Chickpea-Enriched White Bread Boosts Satiety Hormones GLP-1 and PYY in Healthy Humans

This was a double-blind randomized crossover study with 20 healthy participants. Each participant consumed white bread with 0%, 30%, or 60% cellular chickpea powder on separate occasions (50g total starch per serving). Postprandial blood samples were collected to measure GLP-1, PYY, glucose, and insulin responses. Satiety scores were also collected. Complementary in vitro digestion studies were conducted to understand the mechanistic basis for the observed effects. The trial was registered at ClinicalTrials.gov (NCT03994276).

GLP-1 is the same peptide hormone targeted by blockbuster weight-loss drugs like semaglutide (Ozempic/Wegovy). This study shows that a simple dietary modification — using intact chickpea cell flour in bread — can naturally boost GLP-1 and PYY release, potentially offering a food-based strategy for improving satiety and blood sugar control. This has implications for dietary approaches to obesity and cardiometabolic disease prevention.

With the explosion of interest in GLP-1 receptor agonists for weight management, understanding dietary factors that naturally stimulate GLP-1 release is increasingly relevant. This study contributes to the growing evidence that food structure — not just composition — matters for metabolic responses. The cellular flour technology preserves plant cell integrity, creating a slow-release mechanism for nutrients that enhances gut peptide hormone secretion in ways that conventional flour processing destroys.

The sample size was small (n=20), limiting statistical power for subgroup analyses. Only healthy participants were studied, so responses in people with obesity or diabetes may differ. The study measured acute postprandial responses over a single meal; long-term effects on weight or metabolic health were not assessed. The 60% chickpea flour bread may have different taste and texture that could affect real-world acceptability despite the double-blind design.